US 11,945,877 B2
Anti-HER2 antibodies
Cheng-I Wang, Singapore (SG); Lionel Jianrong Low, Singapore (SG); Angeline Goh, Singapore (SG); and Sandy Wen-Hsin Lee, Singapore (SG)
Assigned to Agency for Science, Technology and Research, Singapore (SG)
Appl. No. 16/969,119
Filed by Agency for Science, Technology and Research, Singapore (SG)
PCT Filed Feb. 12, 2019, PCT No. PCT/SG2019/050077
§ 371(c)(1), (2) Date Aug. 11, 2020,
PCT Pub. No. WO2019/160501, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. 10201801219V (SG), filed on Feb. 13, 2018.
Prior Publication US 2021/0139605 A1, May 13, 2021
Int. Cl. C07K 16/32 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. An antibody or antigen binding fragment thereof which is capable of binding to HER2, optionally isolated, wherein the antibody or antigen binding fragment thereof comprises:
a light chain variable region incorporating the following CDRs:
 
 (SEQ ID NO: 255)
 
 LC-CDR1: GLSSGSVSTTYYPS
 
 
 
 (SEQ ID NO: 33)
 
 LC-CDR2: STNTRSS
 
 
 
 (SEQ ID NO: 256)
 
 LC-CDR3: VLYMGNGISV;
a heavy chain variable region incorporating the following CDRs:
 
 (SEQ ID NO: 24)
 
 HC-CDR1: SSSYYWG
 
 
 
 (SEQ ID NO: 25)
 
 HC-CDR2: SIYYSGSTYYNPSLKS
 
 
 
 (SEQ ID NO: 26)
 
 HC-CDR3: YAPDSSGYLVAFDI.